Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score.
Aim: To evaluate active surveillance (AS) selection, safety and durability among men with low-risk prostate cancer assessed using the clinical cell cycle risk (CCR) score, a combined clinical and molecular score. Patients & methods: Initial treatment selection (AS vs treatment) and duration of AS were evaluated for men with low-risk prostate cancer according to the CCR score and National Comprehensive Cancer Network guidelines. Adverse events included biochemical recurrence and metastasis. Results: 82.4% (547/664) of men initially selected AS (median follow-up: 2.2 years), 0.4% (2/547) of whom experienced an adverse event. Two-thirds of patients remained on AS for more than 3 years; patient choice was the most common reason for leaving AS. Conclusion: The CCR score may aid in the identification of men who can safely defer prostate cancer treatment.
Kaul S, Wojno KJ, Stone S, Evans B, Bernhisel R, Meek S, D'Anna RE, Ferguson J, Glaser J, Morgan TM, Lieb J, Yan R, Cohen T, Ehdaie B. Clinical outcomes in men with prostate cancer who selected active surveillance using a clinical cell cycle risk score. Per Med. 2019 Nov;16(6):491-499. doi: 10.2217/pme-2019-0084. Epub 2019 Sep 4. Erratum in: Per Med. 2020 Nov;17(6):491. PMID: 31483217; PMCID: PMC7447833.